On July 2, 2024, Kang Sheng Sequence Source Biotechnology (Wuhan) Co., Ltd (hereinafter referred to as: Kang Sheng Sequence Source) entered into a strategic cooperation with UWEC, and formally announced the inauguration of Kang Sheng Sequence Source Genetic Multi-Organomics DCS Lab Service Center. The center will be a large-scale multi-omics service center based in central China and radiating to the whole country, which will push and help multi-omics research from scientific research to clinical landing, and further consolidate and enhance its innovative development in the field of scientific and technological services and precision medicine.
From left to right: Mr. Chai Haijie, CFO of Kang Sheng Global, Mr. Liu Lei, Co-founder and General Manager of Kang Sheng Sequence Source, Mr. Mou Feng, CEO of Huada Zhizao, Mr. Huang Shiang, Founder and CEO of Kang Sheng Global Group, Mr. Yu Yanfei, Director of Industry Department of Wuhan National Bioindustrial Base Biological Center, and Mr. Tu Zanbing, Chief Operating Officer of Kang Sheng Global attended the meeting.
Huang Shiang, Founder and CEO of Kang Sheng Global Group, and Mou Feng, CEO of Huada Zhizao, cut the ribbon for the launch of DCS Lab Center. Liu Lei, Co-founder and General Manager of Kang Sheng Sequence Source, and Peng Huanhuan, Vice President and General Manager of China Region of Huada Zhizao, signed the contract on behalf of both parties. In addition, Yu Yanfei, Director of Industry Division of Biological Center of Wuhan National Biological Industry Base, Tu Zanbing, COO of Kang Sheng Global, Chai Haijie, CFO of Kang Sheng Global, and Liu Lei, co-founder and general manager of Kang Sheng Sequence Source Biotechnology Ltd. were present at the launching ceremony.
Mr. Huang Shiang, Founder and CEO of Kang Sheng Global, said, "In recent years, many bio-enterprises represented by UWEC have grown from small to large and made great achievements, setting a good example for the industry. Adhering to the concept of win-win cooperation, I sincerely wish that Kang Sheng Xuyuan will give full play to DCS Lab's experience and advantages in the field of histology research to better meet customers' scientific research needs and further accelerate the translation from disease-related target discovery to clinical products."
